PT  - JOURNAL ARTICLE
AU  - Karlijn van der Straten
AU  - Denise Guerra
AU  - Marit J. van Gils
AU  - Ilja Bontjer
AU  - Tom G. Caniels
AU  - Hugo D.G. van Willigen
AU  - Elke Wynberg
AU  - Meliawati Poniman
AU  - Judith A. Burger
AU  - Joey H. Bouhuijs
AU  - Jacqueline van Rijswijk
AU  - Ayesha H.A. Lavell
AU  - Brent Appelman
AU  - Jonne J. Sikkens
AU  - Marije K. Bomers
AU  - Alvin X. Han
AU  - Brooke E. Nichols
AU  - Maria Prins
AU  - Harry Vennema
AU  - Chantal Reusken
AU  - Menno D. de Jong
AU  - Godelieve J. de Bree
AU  - Colin A. Russell
AU  - Dirk Eggink
AU  - Rogier W. Sanders
TI  - Mapping the antigenic diversification of SARS-CoV-2
AID  - 10.1101/2022.01.03.21268582
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.03.21268582
4099  - http://medrxiv.org/content/early/2022/01/03/2022.01.03.21268582.short
4100  - http://medrxiv.org/content/early/2022/01/03/2022.01.03.21268582.full
AB  - Large-scale vaccination campaigns have prevented countless SARS-CoV-2 infections, hospitalizations and deaths. However, the emergence of variants that escape from immunity challenges the effectiveness of current vaccines. Given this continuing evolution, an important question is when and how to update SARS-CoV-2 vaccines to antigenically match circulating variants, similar to seasonal influenza viruses where antigenic drift necessitates periodic vaccine updates. Here, we studied SARS-CoV-2 antigenic drift by assessing neutralizing activity against variants-of-concern (VOCs) of a unique set of sera from patients infected with a range of VOCs. Infections with ancestral or Alpha strains induced the broadest immunity, while individuals infected with other VOCs had more strain-specific responses. Omicron was substantially resistant to neutralization by sera elicited by all other variants. Antigenic cartography revealed that all VOCs preceding Omicron belong to one antigenic cluster, while Omicron forms a new antigenic cluster associated with immune escape and likely requiring vaccine updates to ensure vaccine effectiveness.Competing Interest StatementC.A.R. reports paid advisory roles for Sanofi Pasteur on the epidemiology of influenza viruses and SARS-CoV-2 and for Moderna on the evolution of SARS-CoV-2. None of the other authors have conflicts of interest related to this researchFunding StatementR.W.S. and C.A.R. are recipients of Vici grants from the Netherlands Organization for Scientific Research (NWO). C.A.R. and A.X.H. are also supported by an ERC Consolidator Award. This work was supported by the NOW ZonMw grant agreement no. 10150062010002 to M.D.d.J., and 10430072110003 to G.J. de Bree and the Public Health Service of Amsterdam Research & Development grant number 21-14 to M. Prins (RECoVERED). J.J.S. and M.K.B. are recipients of the NOW grant agreement no. 10430022010023 to J.J.S. and M.K.B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COSCA study, the RECoVERED study and the S3-study were conducted at the Amsterdam University Medical Centres, the Netherlands, and approved the medical ethical review board of the Amsterdam University Medical Centres (NL 73281.018.20, NL73759.018.20, NL73478.029.20, respectively). All individuals provided written informed consent before participating.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors